Favipiravir model FabiFlu from Glenmark has catapulted to seize the primary slot within the home pharma market in April – from 169th in February.
With gross sales of Rs 352 crore in April, this model alone accounted for over 2 per cent of the overall home pharma market gross sales of Rs 15,662 crore.
Based on knowledge from market analysis agency AIOCD AWACS, FabiFlu clocked gross sales of Rs 351.9 crore in April, a greater than seven-fold bounce from March. The second rating model Monocef, an antibiotic, clocked gross sales of Rs 112.9 crore, whereas the third model Zincovit registered gross sales price Rs 94.8 crore.
The large bounce in FabiFlu gross sales occurred owing to a surge in Covid circumstances through the month. Every day recent circumstances touched 401,993 on April 30.
FabiFlu is an oral antiviral drug, which is prescribed to gentle to reasonable Covid sufferers who’re in house quarantine.
In January, gross sales of FabiFlu was Rs 12.4 crore, which slipped additional in February to Rs 11.6 crore. This was when Covid circumstances had been hovering round a couple of thousand circumstances each day.
FabiFlu dislodged an anti-diabetic model Glycomet, which was at rank 2 in each February and March. Glycomet was the highest model within the pharma market in January. Gross sales of this anti-diabetic model have grown from Rs 74.8 crore in January to Rs 82.6 crore in April. Its rating, nonetheless, slipped to 4 in April.
Sometimes, power remedy medicines like anti-diabetic and anti-hypertensive characteristic within the prime 5 drugs manufacturers within the pharma market.
Glenn Saldanha, managing director (MD) and chief govt officer (CEO) of Glenmark stated, “We had been the primary to launch FabiFlu in India for the therapy of gentle to reasonable circumstances and have been enabling its entry to sufferers throughout the nation. We’ll proceed to innovate and discover different promising therapy choices in our core segments.”
Medication which are used to deal with Covid or utilized by folks as immunity boosters have seen a bounce in gross sales and, in flip, rankings. For instance, vitamin C model Limcee jumped from a rank of 433 in January (gross sales of Rs 5.9 crore) to rank 16 in April (gross sales of Rs 50.3 crore). Paracetamol manufacturers Dolo and Calpol characteristic within the prime 20 manufacturers within the pharma market.
The home prescription drugs market has seen a rebound in April, with gross sales rising 51.5 per cent over final yr, because of the low base of April 2020 and a pick-up in demand for Covid-19 medication.
When in comparison with the home gross sales of April 2019, the expansion is round 37 per cent. Nonetheless, in comparison with the earlier month (March 2020), it’s 18.4 per cent.